Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.
AUTOR(ES)
Queener, S F
RESUMO
Trimetrexate and BW301U (piritrexim isethionate), lipid-soluble inhibitors of dihydrofolate reductase, are potent inhibitors of the growth of Pneumocystis carinii in culture with WI-38 cells. Inhibition was observed with 0.1 microgram of trimetrexate or BW301U per ml. Trimethoprim is ineffective at 100 micrograms/ml in this culture system. Both trimetrexate and BW301U were effective as prophylactic agents against P. carinii pneumonia in rats; trimetrexate at 7.5 mg/kg protected 9 of 10 rats, and BW301U at 5 mg/kg protected 4 of 10.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174935Documentos Relacionados
- Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.
- New rat model of Pneumocystis carinii infection.
- Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
- Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
- Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
